Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin

Lulu Iles-Shih, Judith (Judy) Collins, Jennifer L. Holub, David Lieberman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: The fecal occult blood test (FOBT) is widely used for colorectal cancer screening. However, the impact of warfarin use on FOBT sensitivity and specificity remains unclear. This study compares the relative risk of neoplasia in FOBT-positive patients stratified by warfarin use. Methods: The Clinical Outcomes Research Initiative database was used to identify patients with positive FOBT as the only indication for colonoscopy during 2005-2006. Patients were categorized on the basis of documented warfarin status within a 30-day period before FOBT. We compared the demographics and prevalence of significant colon findings (defined as polyp 9 mm or suspected malignant tumor) among the two groups. After adjusting for confounding variables, logistic regression was used to estimate the odds ratio of significant findings in warfarin-positive vs. warfarin-negative patients. Results: Of 10,266 patients with positive FOBT, 372 used warfarin, 9,265 did not use warfarin, and 629 were excluded because of missing warfarin status. Warfarin-positive patients were more likely male (65 vs. 50%; P>0.0001), Caucasian (88 vs. 80%; P>0.0001), and veterans (53 vs. 33%; P>0.0001). The prevalence of a significant finding was greater in the warfarin group, 16 vs. 11.4% (P>0.01). After adjusting for age and sex, the relative risk of significant colon findings among warfarin-positive patients was not significantly different from warfarin-negative patients (odds ratio 1.1, 95% confidence interval: 0.81-1.44). Conclusions: No increased risk for significant colonic findings among FOBT-positive patients according to warfarin use was identified. These findings suggest that continuing warfarin before FOBT will not affect the positive predictive value of this screening test.

Original languageEnglish (US)
Pages (from-to)2030-2034
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume105
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Occult Blood
Hematologic Tests
Warfarin
Neoplasms
Colon
Odds Ratio
Predictive Value of Tests
Confounding Factors (Epidemiology)
Veterans
Colonoscopy
Polyps
Early Detection of Cancer

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin. / Iles-Shih, Lulu; Collins, Judith (Judy); Holub, Jennifer L.; Lieberman, David.

In: American Journal of Gastroenterology, Vol. 105, No. 9, 09.2010, p. 2030-2034.

Research output: Contribution to journalArticle

@article{209de49a231c4d88a7b04ffd061cb8ed,
title = "Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin",
abstract = "Objectives: The fecal occult blood test (FOBT) is widely used for colorectal cancer screening. However, the impact of warfarin use on FOBT sensitivity and specificity remains unclear. This study compares the relative risk of neoplasia in FOBT-positive patients stratified by warfarin use. Methods: The Clinical Outcomes Research Initiative database was used to identify patients with positive FOBT as the only indication for colonoscopy during 2005-2006. Patients were categorized on the basis of documented warfarin status within a 30-day period before FOBT. We compared the demographics and prevalence of significant colon findings (defined as polyp 9 mm or suspected malignant tumor) among the two groups. After adjusting for confounding variables, logistic regression was used to estimate the odds ratio of significant findings in warfarin-positive vs. warfarin-negative patients. Results: Of 10,266 patients with positive FOBT, 372 used warfarin, 9,265 did not use warfarin, and 629 were excluded because of missing warfarin status. Warfarin-positive patients were more likely male (65 vs. 50{\%}; P>0.0001), Caucasian (88 vs. 80{\%}; P>0.0001), and veterans (53 vs. 33{\%}; P>0.0001). The prevalence of a significant finding was greater in the warfarin group, 16 vs. 11.4{\%} (P>0.01). After adjusting for age and sex, the relative risk of significant colon findings among warfarin-positive patients was not significantly different from warfarin-negative patients (odds ratio 1.1, 95{\%} confidence interval: 0.81-1.44). Conclusions: No increased risk for significant colonic findings among FOBT-positive patients according to warfarin use was identified. These findings suggest that continuing warfarin before FOBT will not affect the positive predictive value of this screening test.",
author = "Lulu Iles-Shih and Collins, {Judith (Judy)} and Holub, {Jennifer L.} and David Lieberman",
year = "2010",
month = "9",
doi = "10.1038/ajg.2010.264",
language = "English (US)",
volume = "105",
pages = "2030--2034",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin

AU - Iles-Shih, Lulu

AU - Collins, Judith (Judy)

AU - Holub, Jennifer L.

AU - Lieberman, David

PY - 2010/9

Y1 - 2010/9

N2 - Objectives: The fecal occult blood test (FOBT) is widely used for colorectal cancer screening. However, the impact of warfarin use on FOBT sensitivity and specificity remains unclear. This study compares the relative risk of neoplasia in FOBT-positive patients stratified by warfarin use. Methods: The Clinical Outcomes Research Initiative database was used to identify patients with positive FOBT as the only indication for colonoscopy during 2005-2006. Patients were categorized on the basis of documented warfarin status within a 30-day period before FOBT. We compared the demographics and prevalence of significant colon findings (defined as polyp 9 mm or suspected malignant tumor) among the two groups. After adjusting for confounding variables, logistic regression was used to estimate the odds ratio of significant findings in warfarin-positive vs. warfarin-negative patients. Results: Of 10,266 patients with positive FOBT, 372 used warfarin, 9,265 did not use warfarin, and 629 were excluded because of missing warfarin status. Warfarin-positive patients were more likely male (65 vs. 50%; P>0.0001), Caucasian (88 vs. 80%; P>0.0001), and veterans (53 vs. 33%; P>0.0001). The prevalence of a significant finding was greater in the warfarin group, 16 vs. 11.4% (P>0.01). After adjusting for age and sex, the relative risk of significant colon findings among warfarin-positive patients was not significantly different from warfarin-negative patients (odds ratio 1.1, 95% confidence interval: 0.81-1.44). Conclusions: No increased risk for significant colonic findings among FOBT-positive patients according to warfarin use was identified. These findings suggest that continuing warfarin before FOBT will not affect the positive predictive value of this screening test.

AB - Objectives: The fecal occult blood test (FOBT) is widely used for colorectal cancer screening. However, the impact of warfarin use on FOBT sensitivity and specificity remains unclear. This study compares the relative risk of neoplasia in FOBT-positive patients stratified by warfarin use. Methods: The Clinical Outcomes Research Initiative database was used to identify patients with positive FOBT as the only indication for colonoscopy during 2005-2006. Patients were categorized on the basis of documented warfarin status within a 30-day period before FOBT. We compared the demographics and prevalence of significant colon findings (defined as polyp 9 mm or suspected malignant tumor) among the two groups. After adjusting for confounding variables, logistic regression was used to estimate the odds ratio of significant findings in warfarin-positive vs. warfarin-negative patients. Results: Of 10,266 patients with positive FOBT, 372 used warfarin, 9,265 did not use warfarin, and 629 were excluded because of missing warfarin status. Warfarin-positive patients were more likely male (65 vs. 50%; P>0.0001), Caucasian (88 vs. 80%; P>0.0001), and veterans (53 vs. 33%; P>0.0001). The prevalence of a significant finding was greater in the warfarin group, 16 vs. 11.4% (P>0.01). After adjusting for age and sex, the relative risk of significant colon findings among warfarin-positive patients was not significantly different from warfarin-negative patients (odds ratio 1.1, 95% confidence interval: 0.81-1.44). Conclusions: No increased risk for significant colonic findings among FOBT-positive patients according to warfarin use was identified. These findings suggest that continuing warfarin before FOBT will not affect the positive predictive value of this screening test.

UR - http://www.scopus.com/inward/record.url?scp=77956341755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956341755&partnerID=8YFLogxK

U2 - 10.1038/ajg.2010.264

DO - 10.1038/ajg.2010.264

M3 - Article

C2 - 20683445

AN - SCOPUS:77956341755

VL - 105

SP - 2030

EP - 2034

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -